269 505

Cited 5 times in

Prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving highly active antiretroviral therapy

Authors
 Sang Hoon Han  ;  Bum Sik Chin  ;  Hee Kyoung Choi  ;  So Youn Shin  ;  Yun Tae Chae  ;  Ji-Hyeon Baek  ;  Chang Oh Kim  ;  Jun Yong Choi  ;  Young Goo Song  ;  Hyun Chul Lee  ;  June Myung Kim 
Citation
 TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, Vol.219(2) : 145-153, 2009 
Journal Title
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
ISSN
 0040-8727 
Issue Date
2009
MeSH
Adult ; Antiretroviral Therapy, Highly Active/adverse effects* ; Asian Continental Ancestry Group ; Female ; HIV Infections/complications* ; HIV Infections/drug therapy* ; Humans ; Lipodystrophy/chemically induced* ; Lipodystrophy/complications ; Lipodystrophy/diagnosis ; Lipodystrophy/epidemiology* ; Male ; Middle Aged ; Prevalence ; Regression Analysis ; Republic of Korea/epidemiology
Keywords
Lipoatrophy ; HIV ; Highly active antiretroviral therapy ; Stavudine ; Korea
Abstract
Lipoatrophy is the long-term adverse effects developed in human immunodeficiency virus (HIV)-1-infected subjects receiving highly active antiretroviral therapy (HAART). This cross-sectional study aimed to evaluate the prevalence of and clinical factors associated with lipoatrophy in HIV-infected Koreans receiving HAART for more than 6 months. Lipoatrophy was diagnosed by concordance between physical examination and history taking performed by a single physician. Various covariates were examined, including diabetes mellitus (DM), lipid profiles after HAART, and HAART regimen and duration. Among total 144 patients (6 females and 138 males), 35 patients (24.3%) were diagnosed with lipoatrophy. The prevalence of lipoatrophy was significantly higher in females than that in males [83.3% (5/6) vs. 21.7% (30/138), p = 0.010] and higher in patients with DM than patients without DM [66.7% (4/6 DM) vs. 22.5% (31/138 non-DM), p = 0.030], or in patients with high total cholesterol levels than patients with low total cholesterol levels [31.9% (23/72 patients with high cholesterol) vs. 16.7% (12/72 patients with low cholesterol), p = 0.035]. Moreover, patients with stavudine treatment history (> 12 months) had a higher prevalence of lipoatrophy than patients who never received stavudine [50.0% (15/30) vs. 16.5% (17/103), p < 0.001]. In the multivariate logistic analysis, stavudine treatment for > 12 months (OR, 3.67; p = 0.011) and being female (OR, 24.93; p = 0.009) are independently associated with lipoatrophy. In conclusion, the prevalence of lipoatrophy in HIV-infected Koreans receiving HAART is not uncommon. Limited use of stavudine and regular monitoring are warranted to reduce lipoatrophy
Files in This Item:
T200902814.pdf Download
DOI
10.1620/tjem.219.145
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, June Myung(김준명)
Kim, Chang Oh(김창오) ORCID logo https://orcid.org/0000-0002-0773-5443
Baek, Ji Hyeon(백지현)
Song, Young Goo(송영구) ORCID logo https://orcid.org/0000-0002-0733-4156
Shin, So Youn(신소연)
Lee, Hyun Chul(이현철)
Chin, Bum Sik(진범식)
Chae, Yun Tae(채윤태)
Choi, Jun Yong(최준용) ORCID logo https://orcid.org/0000-0002-2775-3315
Choi, Hee Kyoung(최희경)
Han, Sang Hoon(한상훈) ORCID logo https://orcid.org/0000-0002-4278-5198
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/104406
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links